文献速递消化系统肿瘤

IMAB362(Zolbetuximab)治疗晚期胃癌及胃食管结合部癌的I期剂量递增研究

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
PubMed 文献 · Eur J Cancer · 2018-06-21

这项首次人体I期研究纳入15例晚期胃癌或胃食管结合部癌患者,按3+3设计依次接受33、100、300、600和1000 mg/m2单次剂量递增的IMAB362治疗。IMAB362总体耐受良好,最常见治疗相关不良事件为胃肠道毒性,4周内未观察到剂量限制性毒性,未确定最大耐受剂量;药代动力学呈剂量比例关系,平均半衰期13-24天,600 mg/m2组1例患者获得并维持疾病稳定约2个月。

要点

  • IMAB362在33-1000 mg/m2单次给药范围内总体耐受良好,胃肠道毒性最常见。
  • 4周内未观察到剂量限制性毒性,未确定最大耐受剂量。
  • 药代动力学呈剂量比例关系,平均半衰期13-24天。

核心结论

  • IMAB362总体耐受良好,支持在胃癌/胃食管结合部癌患者中进一步评估。

研究设计与样本

  • 首次人体I期剂量递增研究,纳入15例晚期胃癌或胃食管结合部癌成人患者,按3+3设计依次进入33、100、300、600和1000 mg/m2五个单次剂量递增队列。

主要发现

  • IMAB362在所有剂量下总体耐受良好,胃肠道毒性为最常见的治疗相关不良事件。
  • 4周治疗内未观察到剂量限制性毒性,未确定最大耐受剂量。
  • 药代动力学特征在剂量范围内呈比例关系,平均半衰期范围为13至24天。
  • 单次静脉输注IMAB362后第4-5周,多数患者显示疾病进展,600 mg/m2剂量组1例患者获得并维持疾病稳定约2个月。

临床怎么用

  • 该首次人体I期研究结果支持IMAB362在胃癌/胃食管结合部癌中开展进一步临床评估。

局限性

  • 样本量小(N=15),为单次给药剂量递增设计,未确定最大耐受剂量和II期推荐剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to cancer cells. In vitro, IMAB362 mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; thus, IMAB362 may serve as a potent, targeted immunotherapeutic agent. METHODS: This first-in-human phase I study enroled adult patients (N = 15) with advanced gastric or gastro-oesophageal junction cancer into five sequential single dose-escalation cohorts (33, 100, 300, 600, and 1000 mg/m2) following a 3 + 3 design. Safety/tolerability, including determination of maximum tolerated dose and recommended phase II dose, were the primary objectives; secondary objectives included assessment of the IMAB362 pharmacokinetic profile, immunogenicity, and antitumour activity (assessed by Response Evaluation Criteria in Solid Tumors v1.0). RESULTS: IMAB362 was generally well tolerated at all doses, with gastrointestinal toxicities being the most commonly observed treatment-related adverse events. As dose-limiting toxicity was not observed within 4 weeks of treatment, a maximum tolerated dose was not established. The pharmacokinetic profile of IMAB362 appeared to be proportional across the dose range; and mean half-life ranged from 13 to 24 d. While most patients showed progressive disease at weeks 4-5 after a single intravenous IMAB362 infusion, one patient in the 600 mg/m2 dose group achieved and maintained stable disease for approximately 2 months postinfusion. CONCLUSIONS: Findings from this study demonstrate that IMAB362 is generally well tolerated and support further evaluation in patients with gastric/gastro-oesophageal junction cancer. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov, Identifier NCT00909025.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sahin U, Schuler M, Richly H, et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018. PMID: 29936063. doi:10.1016/j.ejca.2018.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。